{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:38:43Z","timestamp":1788385123537,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K16248"],"award-info":[{"award-number":["21K16248"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","geriatriconcology.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jgo.2022.10.011","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T05:39:34Z","timestamp":1667281174000},"page":"101396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study"],"prefix":"10.1016","volume":"14","author":[{"given":"Takayuki","family":"Hiroi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hosoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodai","family":"Kuriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Mushino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sonoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jgo.2022.10.011_bb0005","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.jgo.2022.10.011_bb0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.jgo.2022.10.011_bb0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3324\/haematol.2014.107300","article-title":"Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010","volume":"100","author":"Issa","year":"2015","journal-title":"Haematologica."},{"issue":"11","key":"10.1016\/j.jgo.2022.10.011_bb0020","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1002\/cam4.1805","article-title":"Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification","volume":"7","author":"Muto","year":"2018","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.jgo.2022.10.011_bb0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jgo.2015.01.003","article-title":"Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma","volume":"6","author":"Carson","year":"2015","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.jgo.2022.10.011_bb0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejca.2018.05.006","article-title":"Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: a Danish population-based cohort study","volume":"99","author":"Juul","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.jgo.2022.10.011_bb0035","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jgo.2022.02.005","article-title":"Geriatric assessment in older adults with non-Hodgkin lymphoma: a young International Society of Geriatric Oncology (YSIOG) review paper","volume":"13","author":"Akhtar","year":"2022","journal-title":"J. Geriatr. Oncol."},{"issue":"4","key":"10.1016\/j.jgo.2022.10.011_bb0040","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","article-title":"Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP","volume":"87","author":"Bosly","year":"2008","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.jgo.2022.10.011_bb0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.13619","article-title":"Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma","volume":"173","author":"Eyre","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.jgo.2022.10.011_bb0050","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.jgo.2022.10.011_bb0055","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.jgo.2022.10.011_bb0060","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/annonc\/mdx413","article-title":"ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma","volume":"29","author":"Buske","year":"2018","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.jgo.2022.10.011_bb0065","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/bloodadvances.2021004665","article-title":"Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review","volume":"5","author":"Bataillard","year":"2021","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.jgo.2022.10.011_bb0070","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/joim.12889","article-title":"Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age","volume":"285","author":"Eyre","year":"2019","journal-title":"J. Intern. Med."},{"issue":"8","key":"10.1016\/j.jgo.2022.10.011_bb0075","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3324\/haematol.2019.234435","article-title":"Impact of relative dose intensity of standard regimens on survival in elderly patients aged 80 years and older with diffuse large B-cell lymphoma","volume":"105","author":"Lee","year":"2020","journal-title":"Haematologica."},{"issue":"1","key":"10.1016\/j.jgo.2022.10.011_bb0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12185-009-0461-8","article-title":"Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin\u2019s lymphoma: single center, 15-year experience","volume":"91","author":"Zhai","year":"2010","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.jgo.2022.10.011_bb0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00432-009-0637-x","article-title":"Phase II study of rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma","volume":"136","author":"Hara","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jgo.2022.10.011_bb0090","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hon.815","article-title":"A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma","volume":"25","author":"Tsurumi","year":"2007","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.jgo.2022.10.011_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.51.1","article-title":"Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma","volume":"51","author":"Yamaguchi","year":"2011","journal-title":"J. Clin. Exp. Hematop."},{"issue":"3","key":"10.1016\/j.jgo.2022.10.011_bb0100","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/cam4.2008","article-title":"The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients","volume":"8","author":"Dlugosz-Danecka","year":"2019","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.jgo.2022.10.011_bb0105","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.jgo.2022.10.011_bb0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428194.2011.600486","article-title":"Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older","volume":"53","author":"Meguro","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.jgo.2022.10.011_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.13704","article-title":"Impact of therapeutic management and geriatric evaluation on patient of eighty years and older with diffuse large B-cell lymphoma on survival: a systematic review","volume":"108","author":"Briand","year":"2022","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"10.1016\/j.jgo.2022.10.011_bb0120","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1080\/10428194.2018.1443332","article-title":"Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era","volume":"59","author":"Beygi","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.jgo.2022.10.011_bb0125","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol."},{"issue":"11","key":"10.1016\/j.jgo.2022.10.011_bb0130","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1200\/JCO.20.02666","article-title":"Subcutaneous rituximab-MiniCHOP compared with subcutaneous rituximab-MiniCHOP plus Lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older","volume":"39","author":"Oberic","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jgo.2022.10.011_bb0135","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","article-title":"Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma","volume":"89","author":"Hirakawa","year":"2010","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.jgo.2022.10.011_bb0140","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/10428194.2016.1211279","article-title":"The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma","volume":"58","author":"Kanemasa","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.jgo.2022.10.011_bb0145","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00277-020-04345-3","volume":"100","author":"Zettl","year":"2021","journal-title":"Ann. Hematol."},{"issue":"11","key":"10.1016\/j.jgo.2022.10.011_bb0150","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.29290","article-title":"Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma","volume":"121","author":"Williams","year":"2015","journal-title":"Cancer."},{"issue":"10","key":"10.1016\/j.jgo.2022.10.011_bb0155","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.7164\/antibiotics.32.1082","article-title":"Tetrahydropyranyl derivatives of daunomycin and adriamycin","volume":"32","author":"Umezawa","year":"1979","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"Suppl. 1","key":"10.1016\/j.jgo.2022.10.011_bb0160","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/00000421-199012001-00005","article-title":"Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin\u2019s lymphoma in the elderly","volume":"13","author":"Kitamura","year":"1990","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jgo.2022.10.011_bb0165","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1532\/IJH97.03147","article-title":"Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin\u2019s lymphoma","volume":"81","author":"Mori","year":"2005","journal-title":"Int. J. Hematol."},{"issue":"4","key":"10.1016\/j.jgo.2022.10.011_bb0170","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/10428194.2011.555024","article-title":"Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma","volume":"52","author":"Kasahara","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.jgo.2022.10.011_bb0175","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s10147-015-0912-6","article-title":"Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy","volume":"21","author":"Iioka","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.jgo.2022.10.011_bb0180","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2169\/internalmedicine.8291-16","article-title":"3A comparison between R-THP-COP and R-CHOP regimens for the treatment of diffuse large B-cell lymphoma in old patients: a single-institution analysis","volume":"56","author":"Araie","year":"2017","journal-title":"Intern. Med."},{"issue":"4","key":"10.1016\/j.jgo.2022.10.011_bb0185","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/hon.2524","article-title":"R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: a randomized, open-label, noninferiority phase 3 trial","volume":"36","author":"Hara","year":"2018","journal-title":"Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.jgo.2022.10.011_bb0190","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1600-0609.1999.tb01137.x","article-title":"Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin\u2019s lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM","volume":"63","author":"Niitsu","year":"1999","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.jgo.2022.10.011_bb0195","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/pbc.23012","article-title":"Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia","volume":"57","author":"Shimomura","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"issue":"34","key":"10.1016\/j.jgo.2022.10.011_bb0200","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1200\/JCO.2017.72.4211","article-title":"Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors","volume":"35","author":"Salz","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jgo.2022.10.011_bb0205","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ajh.26230","article-title":"Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era","volume":"96","author":"Boddicker","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.jgo.2022.10.011_bb0210","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/onco.13610","article-title":"Challenges and opportunities in the Management of Diffuse Large B-cell lymphoma in older patients","volume":"26","author":"Di","year":"2021","journal-title":"Oncologist."}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406822004957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406822004957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T11:43:46Z","timestamp":1724759026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406822004957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1879406822004957"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2022.10.011","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2022.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101396"}}